KTC1101 treatment exhibited a strong anti-proliferative activity against B16 cells, significantly inhibited the PI3K pathway, induced G1 phase arrest, and minimally influenced apoptosis (Supplementary Fig. 5A-F), consistent with observations in other cancer cell lines [48]. The gene discussed is PIK3CG; the disease is cancer.